Dr. Feldman on Durvalumab for Patients With Lung Cancer

Lawrence E. Feldman, MD
Published: Wednesday, Nov 08, 2017



Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Durvalumab is a very exciting agent given the recently announced data that indicates an improvement in overall survival, especially in stage III patients with lung cancer.

This data shows that consolidation therapy after chemoradiation with durvalumab is a very promising combination. As a result, Feldman says he is looking forward to using durvalumab in his own practice.


Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Durvalumab is a very exciting agent given the recently announced data that indicates an improvement in overall survival, especially in stage III patients with lung cancer.

This data shows that consolidation therapy after chemoradiation with durvalumab is a very promising combination. As a result, Feldman says he is looking forward to using durvalumab in his own practice.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x